Comprehensive genomic characterization of prostate cancer has identified recurrent alterations in genes involved in androgen signaling, DNA repair, and PI3K signaling, among others. However, larger and uniform genomic analysis may identify additional recurrently mutated genes at lower frequencies.
Here we aggregate and uniformly analyze exome sequencing data from 1,013 prostate cancers. We identify and validate a new class of E26 transformation-specific (ETS)-fusion-negative tumors defined by mutations in epigenetic regulators, as well as alterations in pathways not previously implicated in prostate cancer, such as the spliceosome pathway. We find that the incidence of significantly mutated genes (SMGs) follows a long-tail distribution, with many genes mutated in less than 3% of cases. We identify a total of 97 SMGs, including 70 not previously implicated in prostate cancer, such as the ubiquitin ligase CUL3 and the transcription factor SPEN. Finally, comparing primary and metastatic prostate cancer identifies a set of genomic markers that may inform risk stratification.
The genomic landscape of primary and metastatic prostate cancer has been robustly assessed through whole-exome sequencing (WES) of tumors and matched germline samples. These studies have identified multiple recurrently altered genes and pathways, including androgen signaling, DNA repair, and phosphoinositide 3-kinase (PI3K)-AKT signaling 1, 2 . Additionally, they identified genomically distinct classes of prostate cancer, defined by ETS transcription family fusions 3 or mutations in SPOP 4 , FOXA1 4 , or IDH1 2 . Nevertheless, prostate cancer harbors substantial interpatient genomic heterogeneity, and power analyses have suggested that larger WES studies may identify additional statistically significant mutated genes occurring at lower frequencies, indicating that the spectrum of genes involved in prostate cancer is incompletely defined 5 . As the aggregation and uniform meta-analysis of WES data has been transformative to research and clinical interpretation of germline genetics 6 , we hypothesized that mutational significance analysis using statistical and biological frameworks in a large and uniformly analyzed WES cohort might similarly identify new genes and pathways to refine the genomic landscape of prostate cancer.
We assembled and uniformly analyzed WES data from 1,013 tumor and matched germline prostate cancers (680 primary and 333 metastatic tumors) (Supplementary Table 1) 1,2,4,7-9 that passed joint quality control parameters ( Table 2 , and Supplementary Note). Patient characteristics, including age at diagnosis, Gleason score, and metastatic site, are shown in Table 1 and Supplementary Table 3 . The mean nonsynonymous mutational load for primary and metastatic prostate cancers was 1.36 mutations/Mb and 2.93 mutations/ Mb, respectively ( Supplementary Fig. 2 ). As previously reported 2 , mutational load was significantly higher in metastatic tumors (P < 0.001, estimated 1.43 mutations/Mb higher mutational load adjusted for differences in tumor sequencing depth and tumor Letters NATurE GENETICS purity) (Methods and Supplementary Fig. 2 ). Additionally, copy number burden was significantly higher in metastatic tumors (P < 0.001). In primary tumors, increased age and higher Gleason score were associated with higher mutation burden (P = 0.02 and P < 0.001, respectively) and copy number burden (P < 0.001 and P < 0.001) (all adjusted for tumor purity and tumor sequencing depth) ( Supplementary Fig. 2 ) 10 .
Mutational significance analysis of point mutations and short indels using MutSig2CV 11 and additional biological significance filters (Methods) identified 97 SMGs (Fig. 1a,b , Supplementary  Figs. 3 and 4a-c, and Supplementary Table 4) . As predicted by prior power analyses 5 , the majority of these new SMGs occurred in less than 5% of the overall cohort and could only be discovered in cohorts with over 900 samples (Supplementary Table 5 ). SMGs TP53  SPOP  KMT2C  KMT2D  FOXA1  AR  ZFHX3  CDK12  PTEN  ATM  APC  KDM6A  SPEN  PIK3CA  CTNNB1  BRCA2  COL5A1  TAF1L  CHD6  NCOR1  MED12  MGA  STAB2  DHX30  ERF  KMT2A  CDC27  PTPRC  JAK1  CHD3  ARID1A  USP28  ZNF292  SETD2  IGF2R  ZMYM3  CDKN1B  RB1  RNF43  BRPF1  COL5A3  TRPM4  CHD1  CHD7  SAMD9  BRAF  PPL  RAG1  SLC4A2  USP7  ARID2  CNOT3  COL15A1  CUL3  EHHADH  ITSN1  RPRD2  ARID4A  IL6ST  MET  NDST2  TBC1D2  MATN4  SMARCA1  MYBBP1A  PAX6  PYHIN1  SETDB1  SF3B1  SPATA18  TMPRSS2  AAMTS8D  JADE2  ETV3  MBD1  NOX3  PALB2  PIK3R1  PIK3R2  RNF31  UNC13D  PIK3CB  CDH1  ITSN2  KEAP1  PDS5A  IDH1  PMS1  ASF3W  KRAS  HRAS  TAP1  XPO1  AKT1  MRE11A  U2AF1 We then integrated focal copy number events and available ETS fusion data to stratify these findings by pathway and function and developed a categorized set of SMGs in prostate cancer. Through this approach, we identified 20% of prostate cancer samples with mutations, frequently truncating, in epigenetic modifiers or chromatinremodeling genes (Fig. 1c,d and Supplementary Table 6 ). Within this class of tumors, 5% had mutations in genes that encode SWI/ SNF nucleosome-remodeling complex members (Fig. 1d) , including ARID1A (1.6%), ARID4A (1%), ARID2 (1.3%), and SMARCA1 (1.1%), similar to observations made in other tumor types 12, 13 . In primary tumors, mutations in genes encoding epigenetic regulators and chromatin modifiers were significantly associated with higher Gleason score (10% Gleason 3 + 4, 22% Gleason 8-10, P = 0.001, Fisher's exact test). Furthermore, upon examination of the subset of our cohort for which ETS fusion status was available (n = 765), we found that alterations in epigenetic regulators and chromatin remodelers were significantly more common in tumors that lacked an ETS fusion (P = 1 × 10
, Fisher's exact test) and in tumors without previously known drivers (ETS fusion, IDH1, SPOP, CUL3, or FOXA1 mutation) (P = 0.007, Fisher's exact test) (Fig. 1c,d and Supplementary Table 6 ).
Our analysis also identified recurrently mutated genes in the ubiquitin-proteasome (USP) and ligase gene family, of which SPOP is a member, with mutations found in USP28 (1.4%), USP7 (1.2%), and CUL3 (1.3%) (Fig. 2a) . CUL3 encodes part of a cullin-RING-based (BTB-CUL3-RBX1) E3 ubiquitin ligase complex with SPOP 14, 15 , and mutations may affect degradation of prostate cancer tumorigenesis regulators, including AR, SRC-3, and TRIM24 16, 17 . CUL3 mutations were primarily in a hotspot (p.Met299Arg) and were mutually exclusive with SPOP mutations (Fig. 2a) , although this cohort size was not sufficiently powered to establish statistical significance. CUL3-mutant tumors also exhibited copy number profiles similar to those of SPOP-mutant tumors, with losses at chromosomes 5q, 6q, and 13 ( Fig. 2b and Supplementary Fig. 5 ) 18 . To confirm this finding in an orthogonal cohort, we identified nine additional somatic CUL3 mutations in an independent cohort of advanced prostate cancers (1.3% in the MSK-IMPACT data 19, 20 ), including three p.Met299Arg alterations ( Supplementary Fig. 6a ).
In addition, the splicing pathway was altered in 4% of prostate tumors (Fig. 2c) , most notably through hotspot mutations in SF3B1 (1.1%) and U2AF1 (0.5%). Mutations in SF3B1 mostly clustered around the highly conserved HEAT repeats in the C terminus ( Fig. 2c) , similar to what is observed in other cancer types 21, 22 . This alteration is thought to disrupt the recognition and binding of 3′ splice sites 23 . We also identified SMGs in previously known prostate cancerassociated pathways, including AR, WNT/β -catenin, PI3K, and RAS-MAPK signaling. Within the AR/hormone signaling pathway, our analysis identified SPEN, which encodes a hormone-inducible transcription repressor, mutated in 2.4% of this cohort, mostly through truncating mutations (Fig. 3a,b) . The SPEN protein is known to repress the estrogen receptor via NCOR2 by recruiting histone deacetylases and SRA, an RNA co-activator 24, 25 . SPEN expression is activated via estrogen and potentially other hormones 25 , and its overexpression is associated with response to tamoxifen in breast cancer 25, 26 . SPEN mutations were significantly enriched in metastatic samples (q = 0.008, Fisher's exact test) and clonal samples ( Fig. 3a) , suggestive of SPEN being a driver in advanced disease.
The PI3K pathway was altered in 25% of our samples, primarily as a result of homozygous loss and truncating mutations in PTEN (16%). Our analysis identified a new prostate cancer-associated gene in the PI3K pathway, PIK3R2 (1%), which, like PIK3R1, encodes a PI3K regulatory subunit 27 . One of the PIK3R2 mutations (encoding p.Asp557Tyr) is paralogous to the known oncogenic p.Asp560Tyr mutation in PIK3R1 ( Supplementary Fig. 6b ) and was also found in our validation cohort.
Genomic alterations in the WNT/β -catenin pathway were found in 10% of the cohort ( Fig. 3c and Supplementary Table 6 ). For CTNNB1, while the majority of mutations clustered in the N-terminal domain (Fig. 3d ), three residues, including a new p.Lys335Ile hotspot, clustered around the region of β -catenin that interacts with AXIN (Fig. 3e) . The RAS-RAF-MAPK pathway was altered in 5% of samples (Supplementary Table 6 ), including SMGs in KRAS and BRAF, mostly due to established hotspot mutations not previously enriched for significance in prostate cancer.
As previously reported, we observed a significant number of inactivating alterations in DNA repair genes (16% of samples; Supplementary Table 6 ). New prostate cancer-specific SMGs in this pathway included MRE11A and PALB2. CDK12 was mutated primarily by truncating mutations (P < 0.001, binomial test), as previously observed in ovarian cancer. Of note, CDK12 missense variants significantly clustered in the kinase domain (P < 0.001, binomial test) ( Supplementary Fig. 6c ), suggesting putative functional relevance. Furthermore, 15 of 31 CDK12-mutant tumors (as well as 27 of 56 samples in the validation cohort) harbored two mutations in the gene, suggestive of frequent biallelic inactivation. Broadly, these results expand on SMGs in known cancer-associated pathways not previously implicated in prostate cancer and further delineate the genomic heterogeneity of mutations in the long tail of this disease.
Finally, we conducted a systematic comparison of primary and metastatic tumors to identify which events are associated with advanced disease (Fig. 4a and Methods). Genes with enrichment in metastatic samples included TP53, AR, PTEN, RB1, FOXA1, APC, and BRCA2 (Fig. 4a) . Alterations in epigenetic regulators, including KMT2C and KMT2D, were also significantly enriched in metastatic tumors and in aggregate define a genomic signature of high-risk disease. Conversely, mutations in SPOP were significantly enriched in primary tumors (Fig. 4a) . After correction for differences in mutational load, IDH1 and ZMYM3 mutations were also enriched in primary tumors (P = 0.01, mutation rate-adjusted permutation test). At the pathway level, PI3K, DNA repair, cell cycle, WNT/β -catenin, 
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and epigenetic regulators were significantly more frequently altered in metastatic than in primary tumors (P < 0.0001, Fisher's exact test; Fig. 4b and Supplementary Table 7) . Within a given cancer type, the ability to redefine mutational significance with rapidly expanding sample sizes may identify new biologically and clinically relevant genes and pathways not previously appreciated. This study has leveraged this strategy to identify new driver genes and pathways potentially implicated in the pathogenesis of prostate cancer. While many of the significantly altered genes and pathways are mutated at low frequencies, given the incidence of prostate cancer, these alterations still impact large patient populations. In addition, whereas expanded analysis of primary indolent prostate cancer suggests near saturation for gene discovery 28 , this analysis, which includes more advanced cases, has identified new biologically and clinically relevant events and creates an opportunity to prospectively assess a metastasis-associated genomic marker for clinical stratification in localized prostate cancer.
Combined statistical and biological significance analysis enabled a focused assessment of the SMGs identified herein, and efforts to functionally characterize this long tail of SMGs in prostate cancer may inform their relative phenotypic effects on oncogenicity, metastatic potential, and response characteristics to known or emerging prostate cancer therapeutics. Indeed, many of the genes identified through statistical analysis alone are of unknown function and 
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suggest that even larger sample sizes paired with functional analysis will be necessary to discriminate which are relevant to prostate cancer oncogenesis. Subsequent studies that harmonize even larger prostate cancer molecular cohorts through uniform genomic analysis may also orthogonally validate these findings and further mitigate technical differences, such as the stochastic effects of sequencing on variant detection, when analyzed in aggregate. Overall, our analysis demonstrates the utility of uniform genomic analysis in a single cancer type at a larger scale than previously reported, thereby redefining the molecular landscape of prostate cancer and providing a rationale to revisit mutational significance in other cancer types as data generation scales by orders of magnitude. 
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Methods
Methods, including statements of data availability and any associated accession codes and references, are available at https://doi. org/10.1038/s41588-018-0083-2. 
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Methods
Cohort collection and quality control. Samples were included in this study if tumor and matched germline whole-exome sequencing raw data (BAM or Fastq files) were accessible and met downstream quality-control characteristics (see "Quality control"). These cohorts were identified through review of the literature and expert review (Supplementary Table 1 ). All cohorts had institutional review board approval for access from the original studies, listed in the citation. We obtained the whole-exome sequencing BAM files from all samples. All samples underwent uniform alignment through the same version of the Picard pipeline. Details of versions and parameters for all tasks within the Picard pipeline are provided in the Supplementary Note. All tumor samples were required to have at least 50× mean target coverage, and all paired normal samples were required to have at least 30× mean target coverage. Mean target coverage across the cohorts for tumors was 104.7× and for normal samples was 103.8× . ContEst was used to estimate the level of contamination with foreign DNA 29 . All samples had ContEst scores lower than 5%, and the mean ContEst value was 0.6%.
Clinical data. All clinicopathological annotations were obtained from the original papers 1, 2, 4, [7] [8] [9] . All primary tumors were treatment naive; all metastatic tumors were castration resistant.
Variant calling.
We restricted the analysis to considering sites in the common pool of bases that covered the bait sets used in the respective source projects, creating an intersected BED file using the bedtools intersect tool ( Supplementary Fig. 7 and Supplementary Table 8) (http://bedtools.readthedocs.io/en/latest/content/ tools/intersect.html). Single-nucleotide variants (SNVs) were called with MuTect (version 1.1.6) 30 , using the intersected BED file. Unfiltered MuTect mutation calls are located in Supplementary Table 9 .
Artifacts introduced by DNA oxidation during sequencing or the formalin fixation process were removed when appropriate 31 . Specifically, regarding artifacts from formalin fixation, formalin fixation introduces multiple types of DNA damage including deamination, which converts cytosine to uracil and leads to downstream mispairing in PCR: C> T/G> A. Because deamination occurs before ligation of palindromic Illumina adaptors, likely deamination artifacts will have a read orientation bias. We used this read orientation to identify artifacts and calculate a Phred-scaled Q score for FFPE artifacts 32 .
To further reduce the number of low-confidence mutations with potential strand bias, we performed a Fisher's exact test on each called mutation site in aggregate to identify variants occurring significantly more frequently in one read direction than in the other. A false discovery rate threshold, measured by Benjamini-Hochberg, of < 0.0001 was used. In addition, all SNVs were required to have an allelic fraction of ≥ 0.01 to be called. Indels were called with Strelka (version 1.0.11) 33 . SNVs and indels were also filtered through a large panel of normal samples to extract additional poor calls. Any mutations in hotspot genes, defined by cancerhotspots.org 34 , initially called by MuTect but subsequently filtered out, were rescued for the final variant list. When possible, we used ERG fusion calls defined according to the original source data 2, 4 . For the 126 additional TCGA samples that were not part of the TCGA manuscript, we derived ERG fusion status via mRNA expression levels, inferring that samples with outlier expression of ERG likely contained an ERG fusion 2 . Exome-wide copy number ratios were inferred from coverage information using ReCapSeg (http://gatkforums.broadinstitute.org/gatk/categories/recapseg). For 303 prostate cancer samples that were analyzed by TCGA, we compared the segmented copy number profiles generated by ReCapSeg to those from SNP6 data 2 ( Supplementary Fig. 8 ). We generated a scatterplot to compare the segment means of matched segments > 200 kb from the SNP6 and ReCapSeg data, resulting in a Pearson correlation of 0.92. Significant focal copy number alterations were identified from segmented data using GISTIC 2.0 35 . In addition, we called the allelic copy number of well-known prostate cancer genes, accounting for purity and ploidy, obtained from FACETS (version 0.5.10) 36 (genes examined: TP53, APC, PTEN, RB1, BRCA2, CDKN1B, FANCA, ATM, AR). We performed manual review of copy number calls for selected oncogenes and tumor suppressors. All data are available for visualization and analysis in the cBioPortal for Cancer Genomics at http://www.cbioportal.org/ 37 .
Mutation and copy number burden. Mutational burden was calculated as the number of mutations over the number of bases covered per sample and is reported as mutations per megabase. Copy number burden was calculated as the fraction of the genome altered using copy number segments with > |0.2|, as previously defined 2 . A multivariate linear regression adjusting for purity and coverage was used to evaluate the difference in mutational and copy number burden in metastatic and primary tumors. Additional information is provided in the Supplementary Note.
Mutational significance analysis. All mutations that passed quality control were analyzed using Mutsig2CV 5 to identify significantly mutated genes (SMGs). Mutsig2CV integrates three separate significance algorithms: MutsigCV; MutsigFN, which looks at the functionality of a mutation in a gene; and MutsigCL, which looks at the clustering of mutations within the gene, specifically looking for hotspot mutations. Both MutsigFN and MutsigCL measure significance based on permutations. SMGs fell within two different categories: (i) q values less than 0.1 and altered in at least 10 samples and (ii) q values between 0.1 and 0.25, altered in 10 samples, and in known cancer-related genes 5, 38 . Additionally, genes with low median allelic fraction (< 0.1) were removed from the SMG list. Genes encoding proteins > 1,500 amino acids in length (except for cancer-related genes 5, 38 and those with a fraction of truncating variants larger than 50% of the total mutations, indicating a putative tumor suppressor) were also removed from the SMG list. Genes with low expression in prostate cancer (median expression below the bottom tertile in TCGA RNA-seq 2 ) were also removed from the SMG list. Finally, genes with at least five oncogenic variants (according to OncoKB; http://oncokb.org/) but that were not previously included in the SMG list were added to the SMG list 39 .
Comparison of genomic alterations between primary and metastatic tumors. Enrichment analysis of mutations and copy number alterations observed in metastatic tumors as compared to primary tumors was performed by tabulating the frequency of mutations or copy number events observed in either metastatic or primary prostate cancer and performing a two-sided Fisher's exact test on a set of biologically relevant cancer-related genes (n = 650 genes) 5, 38 . Multiple-hypothesis test correction was performed using the Benjamini-Hochberg method. To adjust for differences due to increased mutation load in metastatic tumors, we also performed a modified Fisher's exact test, a permutation test where the probability of mutation in each sample is weighted by the mutation rate in that sample, and a simulation of 10,000 permutations performed with a two-sided P value calculated as the proportion of those permutations with the observed or more extreme outcome. This directly corrects for differential observed mutation rates between primary and metastatic tumors and represents the null hypothesis that mutations are equally likely to be found in primary versus metastatic tumors, adjusting for differences in mutation rate. We were able to perform this mutational-ratebased adjustment in genes where the only events were mutations. In cases where functional events included both gene mutations and copy number changes (for example, PTEN), we performed only a Fisher's exact test.
Clonality analysis. Clonality of mutations was estimated as cancer cell fraction (CCF) 40 and implemented in the FACETS algorithm 36 . Additional information is provided in the Supplementary Note. Statistical analysis. Two-tailed Fisher's exact tests were used to assess enrichment of alterations in epigenetic regulators and chromatin remodelers in ETS-fusionnegative tumors. Association of mutation burden and fraction of the genome altered with metastasis status, age at diagnosis, and Gleason score was evaluated using Mann-Whitney Wilcoxon tests and permutation tests. All statistical analyses were performed using R version 3.3.1 (https://www.r-project.org/).
Validation datasets.
To validate mutations detected in this study cohort, we queried cancer panel data from two sources: (i) Foundation Medicine, 204 patients with prostate cancer, as published 41 (mutation calling for this cohort was obtained as previously described and data are available in phs001179) and (ii) clinical sequencing data from 706 samples from Memorial Sloan Kettering patients (MSK-IMPACT) 19,20 (mutation calling for this cohort was obtained as previously described and data are available from the paper or at cBioPortal).
Code availability. Bioinformatics tools used in the analysis of this dataset are publicly available. Any that are not are available upon request.
Life Sciences Reporting Summary. Further information on experimental design is available in the Life Sciences Reporting Summary.
Data availability. BAM files are accessible as described for the original cohorts (Supplementary Table 1 ). In addition, all mutation calls and clinical annotation were deposited into cBioPortal for analysis and visualization: http://www. cbioportal.org/study?id= prad_p1000. 
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